News Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.
News Lilly adds Alzheimer's to its DTC platform LillyDirect Eli Lilly's DTC platform LillyDirect has been expanded to include in-person and telehealth services for people in the US living with Alzheimer's.
News UK sets aside £2m for digitally-enhanced dementia tests The UK is providing £2m in funding to allow digital assessment to be added to a highly-anticipated trial of blood tests for diagnosing dementia.
News End of the line for Cassava's troubled Alzheimer's programme The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.
News Gantenerumab 'shows sign of preventing Alzheimer's dementia' A study has suggested early targeting of amyloid in the brains of people with inherited Alzheimer's can delay symptoms, but not all are convinced.
News NICE agrees to look again at Alzheimer's drug Leqembi Eisai and Biogen have another chance to convince NICE that the NHS should cover the cost of Alzheimer's therapy Leqembi.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl